Scholarlink

Background <p>Radiofrequency rhizotomy (RFR) is one of the primary therapeutic options for managing patients suffering from multiple sclerosis-related trigeminal neuralgia (MS-TN). Given the increasing use of RFR for MS-TN and the absence of consensus on its efficacy, we aimed to assess the clinical application of RFR in this patient population.</p> Methods <p>On April 7, 2025, we conducted a systematic literature search. Studies that evaluated the pain-related outcomes of RFR in MS-TN patients were included.</p> Results <p>Fifteen studies involving 278 MS-TN patients who received RFR were included. The meta-analysis revealed a pooled pain-free rate and adequate pain-relief rate of 78% (95% CI: 58%-93%) and 96% (95% CI: 89%-100%) at the initial follow-up. In addition, the meta-analysis demonstrated a pooled pain-free rate and adequate pain-relief rate of 64% (95% CI: 25%-95%) and 86% (95% CI: 63%-99%), respectively, at the last follow-up. The pooled complication rate in our study was 9% (95% CI: 1%-22%).</p> Conclusions <p>RFR is associated with substantial immediate pain relief rates, reasonable complication rates, and favorable long-term pain-related outcomes. However, the long-term outcomes show considerable variability and should be interpreted cautiously. RFR can be considered one of the main therapeutic options for patients suffering from MS-TN, where the pain has limited their daily performance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Radiofrequency rhizotomy for multiple sclerosis–related trigeminal neuralgia: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月25日

查看全文
  • Bardia Hajikarimloo,
  • Salem M. Tos,
  • Ibrahim Mohammadzadeh,
  • Dorsa Najari,
  • Azin Ebrahimi,
  • Arman Hasanzade,
  • Fatemeh Ghorbanpouryami,
  • Mohammad Amin Habibi

摘要

Background

Radiofrequency rhizotomy (RFR) is one of the primary therapeutic options for managing patients suffering from multiple sclerosis-related trigeminal neuralgia (MS-TN). Given the increasing use of RFR for MS-TN and the absence of consensus on its efficacy, we aimed to assess the clinical application of RFR in this patient population.

Methods

On April 7, 2025, we conducted a systematic literature search. Studies that evaluated the pain-related outcomes of RFR in MS-TN patients were included.

Results

Fifteen studies involving 278 MS-TN patients who received RFR were included. The meta-analysis revealed a pooled pain-free rate and adequate pain-relief rate of 78% (95% CI: 58%-93%) and 96% (95% CI: 89%-100%) at the initial follow-up. In addition, the meta-analysis demonstrated a pooled pain-free rate and adequate pain-relief rate of 64% (95% CI: 25%-95%) and 86% (95% CI: 63%-99%), respectively, at the last follow-up. The pooled complication rate in our study was 9% (95% CI: 1%-22%).

Conclusions

RFR is associated with substantial immediate pain relief rates, reasonable complication rates, and favorable long-term pain-related outcomes. However, the long-term outcomes show considerable variability and should be interpreted cautiously. RFR can be considered one of the main therapeutic options for patients suffering from MS-TN, where the pain has limited their daily performance.